Liver function and survival improve after treatment with Viekirax + Exviera regimen
Hepatitis B and C co-infection linked to worse liver fibrosis than hepatitis B alone
Hepatitis C treatment could halve HCV transmission among gay men in UK over 10 years
Reinfection after hepatitis C cure: prevention may require long-term support for people who have injected drugs
Hepatitis C treatment for people in prison may be highly cost-effective in England
Statin use associated with lower risk of liver decompensation and death in hepatitis C patients with cirrhosis
Civacir immune globulin may help prevent HCV reinfection after liver transplant
Shortening hepatitis C treatment to 6 weeks effective but not perfect for easier-to-treat patients
People with hepatitis C have higher cancer rates, even when excluding liver cancer
Sofosbuvir-based therapy effective for hepatitis C patients with decompensated cirrhosis
Gilead triple combination cures easy-to-treat hepatitis C patients in 6 weeks, but 4 weeks is not enough
Another study confirms detrimental effects of delaying hepatitis C treatment
When a short course of sofosbuvir/ledipasvir fails, some people can be cured of hepatitis C with a double treatment duration
Sofosbuvir-based treatment safe and effective in advanced kidney disease
Merck's grazoprevir/elbasvir combo cures 99% of hepatitis C in chronic kidney disease
Sofosbuvir plus pegylated interferon/ribavirin is highly effective for people with hard-to-treat genotype 3 hepatitis C
Sofosbuvir, daclatasvir and ribavirin cures hepatitis C for most people with advanced cirrhosis or liver transplants
New EASL guidelines prioritise interferon-free hepatitis C treatment
